PATENT CLAIM ANALYSIS

Application Number: 16150610
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "649000"]

Abstract:
This disclosure relates to methods of identifying subjects that have an increased likelihood of responding to a combination of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent and optionally other anticancer agents in the course of chemotherapy. In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent to the subject in need thereof, wherein the subject is in need thereof because measuring a quantity of RNA isolated from a cancer cell from the subject indicates an increased quantity of the RNA compared to a normal sample, wherein the RNA is associated with one or more of the following genes/pseudogenes GLS, UBEC2, HACL1, MSI2, and LOC100129585.

Claim (Index 2):
The method of  claim 1 , wherein the poly (ADP) ribose polymerase enzyme inhibitor is veliparib.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 97.0
- Lexical Diversity: 1.88
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14774772', '15524242', '15305883', '14367341', '15242249']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6938654149077289
- 35 USC 102 Novelty (BERT): 0.4815836189840536
- Combined Prediction Score: 0.6726372353153615
- Mean Citation Score: 173.25249
- Max Citation Score: 185.2743
- Similarity Product: 147.23569107897882

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test